Youchao Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Youchao Dai has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Xinchun Chen
Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, Shenzhen University Medical School
5 shared publications - Huihua Zhang
Shenzhen University
4 shared publications - Yi Cai
Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, Shenzhen University Medical School, Shenzhen, China
4 shared publications Chenyan Shi
School of Medicine, Shenzhen University
2 shared publicationsChuanzhi Zhu
Laboratory of Molecular Biology, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's Republic of China
2 shared publicationsGaoyan Wang
Guangzhou Medical Research Institute of Infectious Diseases, Infectious Disease Center, Guangzhou Eighth People’s Hospital, Guangzhou Medical University
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Photo Quiz: Ring-enhancing cerebral lesions in a patient with advanced HIV
A 55-year-old Chinese woman with advanced HIV infection was admitted with a 1-day history of fever, nausea, and headache, followed by transient loss of consciousness accompanied by incontinence. Since symptom onset, her mental status, appetite, and sleep had remained largely normal. Her fever partially improved after empirical antibiotic therapy.
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Open AccessPhoto Quiz: Ring-enhancing cerebral lesions in a patient with advanced HIV
A 55-year-old Chinese woman with advanced HIV infection was admitted with a 1-day history of fever, nausea, and headache, followed by transient loss of consciousness accompanied by incontinence. Since symptom onset, her mental status, appetite, and sleep had remained largely normal. Her fever partially improved after empirical antibiotic therapy.
- Open Access
- 8 September 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (9) , e1014553
TRIM21 blocks DDX3X-driven stress granule formation during Mycobacterium tuberculosis infection via a non-canonical E3 ligase mechanism
Tripartite motif-containing 21 (TRIM21) is an E3 ubiquitin ligase that binds viral and host proteins to mediate antiviral defense. Its role in Mycobacterium tuberculosis ( Mtb ) infection, however, is unclear. Here, our analysis of human TB transcriptomic datasets showed that TRIM21 expression levels correlate with TB progression in human patients. We further demonstrated that TRIM21 deficiency suppresses Mtb growth in both macrophages and a murine model of tuberculosis (TB). Mechanistically, TRIM21 limits host resistance to Mtb through a non-canonical pathway distinct with its E3 ligase activity. It physically interacts with the RNA helicase DEAD-box helicase family member DDX3X and disrupts phase separation dynamics required for stress granule (SG) assembly. Impaired SG formation compromises innate immune responses, thereby facilitating intracellular bacterial growth and creating a permissive cellular environment for Mtb growth. Consistent with these genetic findings, pharmacological inhibition of TRIM21 restricted Mtb growth in experimental macrophage and murine models. Together, these findings uncover a non-canonical role of TRIM21 in Mtb infection and highlight its potential as a therapeutic target for host-directed therapy against TB.
- 8 September 2026
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (9) , e1014553
Open AccessTRIM21 blocks DDX3X-driven stress granule formation during Mycobacterium tuberculosis infection via a non-canonical E3 ligase mechanism
Tripartite motif-containing 21 (TRIM21) is an E3 ubiquitin ligase that binds viral and host proteins to mediate antiviral defense. Its role in Mycobacterium tuberculosis ( Mtb ) infection, however, is unclear. Here, our analysis of human TB transcriptomic datasets showed that TRIM21 expression levels correlate with TB progression in human patients. We further demonstrated that TRIM21 deficiency suppresses Mtb growth in both macrophages and a murine model of tuberculosis (TB). Mechanistically, TRIM21 limits host resistance to Mtb through a non-canonical pathway distinct with its E3 ligase activity. It physically interacts with the RNA helicase DEAD-box helicase family member DDX3X and disrupts phase separation dynamics required for stress granule (SG) assembly. Impaired SG formation compromises innate immune responses, thereby facilitating intracellular bacterial growth and creating a permissive cellular environment for Mtb growth. Consistent with these genetic findings, pharmacological inhibition of TRIM21 restricted Mtb growth in experimental macrophage and murine models. Together, these findings uncover a non-canonical role of TRIM21 in Mtb infection and highlight its potential as a therapeutic target for host-directed therapy against TB.
- Open Access
- 6 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1477
Genome-Wide Identification and Expression Analysis of the Aspartic Protease Gene Family and Their Responses to Abiotic Stress in Talaromyces marneffei
Aspartic proteases (APs), a class of proteolytic enzymes involved in protein maturation, degradation, and signaling, are known to contribute to fungal virulence and pathogenicity. However, the AP gene family in Talaromyces marneffei (T. marneffei), a dimorphic opportunistic pathogenic fungus, has not yet been functionally analyzed. In this study, we identified 27 AP genes from the T. marneffei genome, and the encoded APs retained conserved domains and exhibited similar motifs and structural properties crucial for catalytic activity. Phylogenetic and collinearity analyses found that TmAPs were most recently homologous to Aspergillus gene families, with both tandem and segmental duplications contributing to their expansion. Expression patterns, combined with RNA-sequencing data, revealed the specialized roles of TmAP1 and TmAP2 in the dimorphic conversion between the yeast and mycelial phases. Protein–protein interaction network analysis uncovered links to cell fusion, mitochondrial function, and programmed cell death. Under abiotic stress conditions, several TmAP genes displayed significant transcriptional changes, implying their involvement in short-term adaptation and stress responses. This study provides the first comprehensive and systematic analysis of the AP gene family in T. marneffei, highlighting their potential biological roles in fungal development, dimorphic conversion, and stress adaptation. Our findings offer valuable insights into further functional characterization of AP genes in T. marneffei and may facilitate the development of novel therapeutic targets and intervention strategies against T. marneffei infection.
- 6 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1477
Open AccessGenome-Wide Identification and Expression Analysis of the Aspartic Protease Gene Family and Their Responses to Abiotic Stress in Talaromyces marneffei
Aspartic proteases (APs), a class of proteolytic enzymes involved in protein maturation, degradation, and signaling, are known to contribute to fungal virulence and pathogenicity. However, the AP gene family in Talaromyces marneffei (T. marneffei), a dimorphic opportunistic pathogenic fungus, has not yet been functionally analyzed. In this study, we identified 27 AP genes from the T. marneffei genome, and the encoded APs retained conserved domains and exhibited similar motifs and structural properties crucial for catalytic activity. Phylogenetic and collinearity analyses found that TmAPs were most recently homologous to Aspergillus gene families, with both tandem and segmental duplications contributing to their expansion. Expression patterns, combined with RNA-sequencing data, revealed the specialized roles of TmAP1 and TmAP2 in the dimorphic conversion between the yeast and mycelial phases. Protein–protein interaction network analysis uncovered links to cell fusion, mitochondrial function, and programmed cell death. Under abiotic stress conditions, several TmAP genes displayed significant transcriptional changes, implying their involvement in short-term adaptation and stress responses. This study provides the first comprehensive and systematic analysis of the AP gene family in T. marneffei, highlighting their potential biological roles in fungal development, dimorphic conversion, and stress adaptation. Our findings offer valuable insights into further functional characterization of AP genes in T. marneffei and may facilitate the development of novel therapeutic targets and intervention strategies against T. marneffei infection.
Plasma miRNA signature for the diagnosis of pulmonary tuberculosis in symptomatic patients
Background: The prompt and precise diagnosis of active pulmonary tuberculosis (TB) is crucial for controlling this disease and yet it remains a global challenge. The objective of this study was to identify a set of microRNAs (miRNAs) whose expression in plasma could be used as a triage test for diagnosing TB. Methods: A total of 879 plasma samples were collected in seven clinical centres from healthy individuals and patients displaying TB-like symptoms and/or radiological features consistent with TB. The samples were classified as TB, pneumonia, lung cancer and HC subgroups based on subsequent diagnostic assessments. We performed quantitative profiling of 264 plasma miRNAs in a training cohort (n=410) and an independent external test cohort (n=469). After dimensionality reduction and feature selection analysis, we identified nine discriminative miRNAs and used them to train an ensemble model in a training cohort using the scikit-learn library, which was subsequently evaluated in the external test cohort. Results: The ensemble model showed notable accuracy in discriminating TB from non-TB patients, yielding areas under the curve (AUC) of 0.84 (95% CI 0.80 to 0.88) for the training cohort and 0.86 (95% CI 0.82 to 0.90) for the external test cohort. When tested against subgroups of laboratory confirmed and clinically diagnosed but unconfirmed TB, the AUC values were 0.89 (95% CI 0.85 to 0.93) and 0.83 (95% CI 0.79 to 0.88), respectively. In smear-negative confirmed TB patients, the AUC exceeded 0.83, with a sensitivity and specificity of 0.75. Conclusions: Our miRNA ensemble model, based on detecting a nine-miRNA expression biosignature in plasma, demonstrated promising ability to diagnose TB and distinguish it from other common lung diseases but further studies are needed to assess its clinical applicability. Trial registration number: ChiCTR2000039734.
Plasma miRNA signature for the diagnosis of pulmonary tuberculosis in symptomatic patients
Background: The prompt and precise diagnosis of active pulmonary tuberculosis (TB) is crucial for controlling this disease and yet it remains a global challenge. The objective of this study was to identify a set of microRNAs (miRNAs) whose expression in plasma could be used as a triage test for diagnosing TB. Methods: A total of 879 plasma samples were collected in seven clinical centres from healthy individuals and patients displaying TB-like symptoms and/or radiological features consistent with TB. The samples were classified as TB, pneumonia, lung cancer and HC subgroups based on subsequent diagnostic assessments. We performed quantitative profiling of 264 plasma miRNAs in a training cohort (n=410) and an independent external test cohort (n=469). After dimensionality reduction and feature selection analysis, we identified nine discriminative miRNAs and used them to train an ensemble model in a training cohort using the scikit-learn library, which was subsequently evaluated in the external test cohort. Results: The ensemble model showed notable accuracy in discriminating TB from non-TB patients, yielding areas under the curve (AUC) of 0.84 (95% CI 0.80 to 0.88) for the training cohort and 0.86 (95% CI 0.82 to 0.90) for the external test cohort. When tested against subgroups of laboratory confirmed and clinically diagnosed but unconfirmed TB, the AUC values were 0.89 (95% CI 0.85 to 0.93) and 0.83 (95% CI 0.79 to 0.88), respectively. In smear-negative confirmed TB patients, the AUC exceeded 0.83, with a sensitivity and specificity of 0.75. Conclusions: Our miRNA ensemble model, based on detecting a nine-miRNA expression biosignature in plasma, demonstrated promising ability to diagnose TB and distinguish it from other common lung diseases but further studies are needed to assess its clinical applicability. Trial registration number: ChiCTR2000039734.
- 1 May 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 216, 108528
Mycobacterium tuberculosis Rv3875 upregulates TRIM21 expression through the type I interferon/STAT1 pathway and promotes intracellular growth
- 1 May 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 216, 108528
Mycobacterium tuberculosis Rv3875 upregulates TRIM21 expression through the type I interferon/STAT1 pathway and promotes intracellular growth
- Open Access
- 23 December 2024
- Published by Elsevier in Journal of Infection
- Vol. 90 (1) , 106384
Hemophagocytic lymphohistiocytosis is associated with disseminated tuberculosis in patients with advanced HIV infection
- 23 December 2024
- Published by Elsevier in Journal of Infection
- Vol. 90 (1) , 106384
Open AccessHemophagocytic lymphohistiocytosis is associated with disseminated tuberculosis in patients with advanced HIV infection
- Open Access
Serum cytokine biosignatures for identification of tuberculosis among HIV-positive inpatients
Background: Serum cytokines correlate with tuberculosis (TB) progression and are predictors of TB recurrence in people living with HIV. We investigated whether serum cytokine biosignatures could diagnose TB among HIV-positive inpatients.Methods: We recruited HIV-positive inpatients with symptoms of TB and measured serum levels of inflammation biomarkers including IL-2, IL-4, IL-6, IL-10, tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ). We then built and tested our TB prediction model.Results: 236 HIV-positive inpatients were enrolled in the first cohort and all the inflammation biomarkers were significantly higher in participants with microbiologically confirmed TB than those without TB. A binary support vector machine (SVM) model was built, incorporating the data of four biomarkers (IL-6, IL-10, TNF-α and IFN-γ). Efficacy of the SVM model was assessed in training (n=189) and validation (n=47) sets with area under the curve (AUC) of 0.92 (95% CI 0.88 to 0.96) and 0.85 (95% CI 0.72 to 0.97), respectively. In an independent test set (n=110), the SVM model yielded an AUC of 0.85 (95% CI 0.76 to 0.94) with 78% (95% CI 68% to 87%) specificity and 85% (95% CI 66% to 96%) sensitivity. Moreover, the SVM model outperformed interferon-gamma release assay (IGRA) among advanced HIV-positive inpatients irrespective of CD4+T-cell counts, which may be an alternative approach for identifyingMycobacterium tuberculosisinfection among HIV-positive inpatients with negative IGRA.Conclusions: The four-cytokine biosignature model successfully identified TB among HIV-positive inpatients. This diagnostic model may be an alternative approach to diagnose TB in advanced HIV-positive inpatients with low CD4+T-cell counts.
Open AccessSerum cytokine biosignatures for identification of tuberculosis among HIV-positive inpatients
Background: Serum cytokines correlate with tuberculosis (TB) progression and are predictors of TB recurrence in people living with HIV. We investigated whether serum cytokine biosignatures could diagnose TB among HIV-positive inpatients.Methods: We recruited HIV-positive inpatients with symptoms of TB and measured serum levels of inflammation biomarkers including IL-2, IL-4, IL-6, IL-10, tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ). We then built and tested our TB prediction model.Results: 236 HIV-positive inpatients were enrolled in the first cohort and all the inflammation biomarkers were significantly higher in participants with microbiologically confirmed TB than those without TB. A binary support vector machine (SVM) model was built, incorporating the data of four biomarkers (IL-6, IL-10, TNF-α and IFN-γ). Efficacy of the SVM model was assessed in training (n=189) and validation (n=47) sets with area under the curve (AUC) of 0.92 (95% CI 0.88 to 0.96) and 0.85 (95% CI 0.72 to 0.97), respectively. In an independent test set (n=110), the SVM model yielded an AUC of 0.85 (95% CI 0.76 to 0.94) with 78% (95% CI 68% to 87%) specificity and 85% (95% CI 66% to 96%) sensitivity. Moreover, the SVM model outperformed interferon-gamma release assay (IGRA) among advanced HIV-positive inpatients irrespective of CD4+T-cell counts, which may be an alternative approach for identifyingMycobacterium tuberculosisinfection among HIV-positive inpatients with negative IGRA.Conclusions: The four-cytokine biosignature model successfully identified TB among HIV-positive inpatients. This diagnostic model may be an alternative approach to diagnose TB in advanced HIV-positive inpatients with low CD4+T-cell counts.
- 17 May 2023
- Published by Taylor & Francis in Autophagy
- Vol. 20 (4) , 943-945
Mycobacterium tuberculosis induces host autophagic ferritin degradation for enhanced iron bioavailability and bacterial growth
Mtb, Mycobacterium tuberculosis; TB, tuberculosis; NCOA4, nuclear receptor coactivator 4; p38, p38 protein kinase; AKT1, AKT serine/threonine kinase 1; TRIM21, tripartite motif containing 21; FTH1, ferritin heavy chain 1; FTL, ferritin light chain; HERC2, HECT and RLD domain containing E3 ubiquitin protein ligase 2.
- 17 May 2023
- Published by Taylor & Francis in Autophagy
- Vol. 20 (4) , 943-945
Mycobacterium tuberculosis induces host autophagic ferritin degradation for enhanced iron bioavailability and bacterial growth
Mtb, Mycobacterium tuberculosis; TB, tuberculosis; NCOA4, nuclear receptor coactivator 4; p38, p38 protein kinase; AKT1, AKT serine/threonine kinase 1; TRIM21, tripartite motif containing 21; FTH1, ferritin heavy chain 1; FTL, ferritin light chain; HERC2, HECT and RLD domain containing E3 ubiquitin protein ligase 2.
- Top Cited PapersOpen Access
- 17 April 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (8)
Mycobacterium tuberculosis hijacks host TRIM21- and NCOA4-dependent ferritinophagy to enhance intracellular growth
Ferritin, a key regulator of iron homeostasis in macrophages, has been reported to confer host defenses against Mycobacterium tuberculosis (Mtb) infection. Nuclear receptor coactivator 4 (NCOA4) was recently identified as a cargo receptor in ferritin degradation. Here, we show that Mtb infection enhanced NCOA4-mediated ferritin degradation in macrophages, which in turn increased the bioavailability of iron to intracellular Mtb and therefore promoted bacterial growth. Of clinical relevance, the upregulation of FTH1 in macrophages was associated with tuberculosis (TB) disease progression in humans. Mechanistically, Mtb infection enhanced NCOA4-mediated ferritin degradation through p38/AKT1- and TRIM21-mediated proteasomal degradation of HERC2, an E3 ligase of NCOA4. Finally, we confirmed that NCOA4 deficiency in myeloid cells expedites the clearance of Mtb infection in a murine model. Together, our findings revealed a strategy by which Mtb hijacks host ferritin metabolism for its own intracellular survival. Therefore, this represents a potential target for host-directed therapy against tuberculosis.
- 17 April 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (8)
Top Cited PapersOpen AccessMycobacterium tuberculosis hijacks host TRIM21- and NCOA4-dependent ferritinophagy to enhance intracellular growth
Ferritin, a key regulator of iron homeostasis in macrophages, has been reported to confer host defenses against Mycobacterium tuberculosis (Mtb) infection. Nuclear receptor coactivator 4 (NCOA4) was recently identified as a cargo receptor in ferritin degradation. Here, we show that Mtb infection enhanced NCOA4-mediated ferritin degradation in macrophages, which in turn increased the bioavailability of iron to intracellular Mtb and therefore promoted bacterial growth. Of clinical relevance, the upregulation of FTH1 in macrophages was associated with tuberculosis (TB) disease progression in humans. Mechanistically, Mtb infection enhanced NCOA4-mediated ferritin degradation through p38/AKT1- and TRIM21-mediated proteasomal degradation of HERC2, an E3 ligase of NCOA4. Finally, we confirmed that NCOA4 deficiency in myeloid cells expedites the clearance of Mtb infection in a murine model. Together, our findings revealed a strategy by which Mtb hijacks host ferritin metabolism for its own intracellular survival. Therefore, this represents a potential target for host-directed therapy against tuberculosis.
- Open Access
Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak
The ongoing SARS-CoV-2 outbreak has killed over twenty-one thousand and sickened over four hundred thousand people worldwide, posing a great challenge to global public health. A sensitive and accurate diagnosis method will substantially help to control disease expansion. Here, we developed a chemiluminescence-immunoassay method based on the recombinant nucleocapsid antigen and the magnetic beads for diagnosis of SARS-CoV-2 infections and surveillance of antibody changing pattern. Serums from 29 healthy individuals, 51 tuberculosis patients, and 79 SARS-CoV-2 confirmed patients were employed to evaluate the performance of this approach. Compared to the IgM testing, the IgG testing was more reliable in which it identified 65 SARS-CoV-2 infections from the 79 confirmed patients and only two false-positive cases from the 80 control group with a sensitivity and specificity reaching 82.28% and 97.5%, respectively. However, only a slight difference (not statistically significant) in the detected cases of SARS-CoV-2 infections was observed between the IgM and IgG testing manner in patients at a different time of onset of disease. A performance comparison between an ELISA kit using the same nucleocapsid antigen and our chemiluminescence method was undertaken. The same false-positive cases were seen in both methods from the paired control group, while ELISA kit can only detect half of the SARS-CoV-2 infections from paired SARS-CoV-2 confirmed patients group than that of the chemiluminescence method, indicating a higher performance for the chemiluminescence-immunoassay approach. Together, our studies provide a useful and valuable serological testing tool for the diagnosis of SARS-CoV-2 infections in the community.
Open AccessEvaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak
The ongoing SARS-CoV-2 outbreak has killed over twenty-one thousand and sickened over four hundred thousand people worldwide, posing a great challenge to global public health. A sensitive and accurate diagnosis method will substantially help to control disease expansion. Here, we developed a chemiluminescence-immunoassay method based on the recombinant nucleocapsid antigen and the magnetic beads for diagnosis of SARS-CoV-2 infections and surveillance of antibody changing pattern. Serums from 29 healthy individuals, 51 tuberculosis patients, and 79 SARS-CoV-2 confirmed patients were employed to evaluate the performance of this approach. Compared to the IgM testing, the IgG testing was more reliable in which it identified 65 SARS-CoV-2 infections from the 79 confirmed patients and only two false-positive cases from the 80 control group with a sensitivity and specificity reaching 82.28% and 97.5%, respectively. However, only a slight difference (not statistically significant) in the detected cases of SARS-CoV-2 infections was observed between the IgM and IgG testing manner in patients at a different time of onset of disease. A performance comparison between an ELISA kit using the same nucleocapsid antigen and our chemiluminescence method was undertaken. The same false-positive cases were seen in both methods from the paired control group, while ELISA kit can only detect half of the SARS-CoV-2 infections from paired SARS-CoV-2 confirmed patients group than that of the chemiluminescence method, indicating a higher performance for the chemiluminescence-immunoassay approach. Together, our studies provide a useful and valuable serological testing tool for the diagnosis of SARS-CoV-2 infections in the community.